Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone propionate/formoterol fumarate/glycopyrrolate - Glenmark Pharmaceuticals

Next Previous
Drug Profile

Fluticasone propionate/formoterol fumarate/glycopyrrolate - Glenmark Pharmaceuticals

Alternative Names: AIRZ-FF; Fluticasone propionate/glycopyrrolate/formoterol fumarate; Glycopyrrolate/formoterol fumarate/fluticasone propionate; Single inhaler triple therapy - Glenmark Pharmaceuticals

Latest Information Update: 06 Nov 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Antispasmodics; Antiulcers; Bronchodilators; Ethanolamines; Glucocorticoids; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 11 May 2020 Launched for Chronic obstructive pulmonary disease in India (Inhalation, Liquid) - First global launch
  • 11 May 2020 Launched for Chronic obstructive pulmonary disease in India (Inhalation, Powder) - First global launch
  • 20 Feb 2020 Glenmark Pharmaceuticals complete a phase III clinical trials in Chronic obstructive pulmonary disease in India (Inhalation) (CTRI2019-01-017156)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top